The first biotech IPO of the new decade has landed — and of course it's another cancer drug developer

The first biotech IPO of 2020 is here, and it’s for a company founded by two marquee names in oncology.

Cambridge-based Black Diamond Therapeutics filed on Friday for an IPO worth up to $100 million, becoming the first biotech of the decade to announce their intention to go public. They’ll use their proceeds to bring their new oncogene approach into the clinic.